Key result
Low systolic blood pressure in treated non-proteinuric CKD remains debated as either a direct cause of cardiovascular harm or a marker of underlying cardiac vulnerability.
Why the study?
Does low systolic blood pressure in treated non-proteinuric CKD indicate cardiovascular harm or serve as a marker of cardiac vulnerability?
Does low systolic blood pressure in treated non-proteinuric CKD indicate cardiovascular harm or serve as a marker of cardiac vulnerability?
This paper discusses the clinical implications of low systolic blood pressure in treated non-proteinuric CKD, specifically whether it causes direct cardiovascular harm or is a marker of underlying cardiac vulnerability.
Hypertension Research - Low systolic blood pressure in treated non-proteinuric CKD: cardiovascular harm or a marker of cardiac vulnerability?
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question. Low systolic blood pressure in treated non-proteinuric CKD remains debated as either a direct cause of cardiovascular harm or a marker of underlying cardiac vulnerability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: